Posted in | News | Nanomedicine | Nanofluidics

Fluidigm Introduces Amplicon Tagging Protocol for Illumina GA II Next-Generation Sequencer

Fluidigm Corporation today announced the release of its amplicon tagging protocol for the Illumina GA II next-generation sequencer. The 48.48 Access Array integrated fluidic circuit (IFC) allows Illumina GA II users to automatically prepare sequencing-ready libraries from 48 individual samples at a time, for as little as $7 (U.S.) per sample.

Fluidigm’s Access Array IFC, when used with an Illumina GA II sequencer, can capture up to 12 kb of sequence data per sample, or 576 kb per array. With upcoming applications on the Access Array system, such as long range PCR, users will be able to target up to 480 kb of sequence data per sample, or 23MB per array.

“Fluidigm’s Access Array system is a unique platform that allows users to prepare sequencing-ready libraries for major next-generation sequencers, such as the Illumina GA II, at a fraction of the cost when compared to traditional methods,” said Mike Lee, Fluidigm’s Senior Director of Marketing. “Fluidigm's Access Array system allows for different approaches to targeted sequence enrichment enabling researchers to choose the sequencer of their choice.”

Sequencing library preparation for next-generation sequencers is by far the most time and labor intensive component of the entire next-generation sequencing process. While typically necessary for whole genome sequencing studies, library preparation can be almost entirely eliminated for targeted re-sequencing projects through the use of amplicon tagging. By incorporating adaptor sequences into the primer design, Access Array’s PCR-based output is ready to go into a GA II flowcell because the necessary capture sequences have already been incorporated.

Fluidigm’s Access Array is the first integrated fluidic circuit that features the capability of harvesting a processed sample out of the chip. Once the sample processing has been completed, the Access Array chip automatically returns the processed sample to ports where it can be easily extracted and readied for sequencing.

Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science research. Fluidigm’s IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These “integrated circuits for biology” are made possible by miniaturizing and integrating liquid handling components on a single microfluidic device (IFC). Fluidigm’s systems, consisting of instrumentation, software and single-use chips, increase throughput, decrease costs and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the Food and Drug Administration for use as a diagnostic and are only available for research use.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Standard BioTools. (2019, February 14). Fluidigm Introduces Amplicon Tagging Protocol for Illumina GA II Next-Generation Sequencer. AZoNano. Retrieved on November 21, 2024 from https://www.azonano.com/news.aspx?newsID=15858.

  • MLA

    Standard BioTools. "Fluidigm Introduces Amplicon Tagging Protocol for Illumina GA II Next-Generation Sequencer". AZoNano. 21 November 2024. <https://www.azonano.com/news.aspx?newsID=15858>.

  • Chicago

    Standard BioTools. "Fluidigm Introduces Amplicon Tagging Protocol for Illumina GA II Next-Generation Sequencer". AZoNano. https://www.azonano.com/news.aspx?newsID=15858. (accessed November 21, 2024).

  • Harvard

    Standard BioTools. 2019. Fluidigm Introduces Amplicon Tagging Protocol for Illumina GA II Next-Generation Sequencer. AZoNano, viewed 21 November 2024, https://www.azonano.com/news.aspx?newsID=15858.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.